We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

107 hedge funds and large institutions have $210M invested in Rigel Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 42 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

8.92% more ownership

Funds ownership: 0% → 8.92% (+8.9%)

12% less funds holding

Funds holding: 121 → 107 (-14)

23% less call options, than puts

Call options by funds: $202K | Put options by funds: $262K

26% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 42

33% less capital invested

Capital invested by funds: $316M → $210M (-$105M)

48% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 27

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
107
Holders Change
-14
Holders Change %
-11.57%
% of All Funds
2.67%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
31
Reduced
42
Closed
27
Calls
$202K
Puts
$262K
Net Calls
-$60K
Net Calls Change
-$2.04M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$16.5M
2
BBA
Baker Bros. Advisors
New York
+$5.78M
3
CAM
Cormorant Asset Management
Massachusetts
+$4.91M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.12M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.87M

Top Sellers

1
BC
Boxer Capital
California
-$4.96M
2
SAM
Senzar Asset Management
New York
-$3.33M
3
Goldman Sachs
Goldman Sachs
New York
-$3.3M
4
PAI
Palo Alto Investors
California
-$2.89M
5
EI
EAM Investors
California
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$35.3M +$1.87M +65,213 +5%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$25.1M +$16.5M +574,489 +119%
O
3
OppenheimerFunds
New York
$11.9M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.3M -$363K -12,685 -3%
BFA
5
BlackRock Fund Advisors
California
$10.4M +$1.56M +54,463 +14%
PAI
6
Palo Alto Investors
California
$9.94M -$2.89M -100,947 -19%
BIT
7
BlackRock Institutional Trust
California
$8.07M +$315K +11,001 +3%
NMC
8
NEA Management Company
Maryland
$7.72M – – –
Citadel Advisors
9
Citadel Advisors
Florida
$7.24M -$1.32M -46,153 -13%
CAM
10
Cormorant Asset Management
Massachusetts
$6.83M +$4.91M +171,310 +148%
BBA
11
Baker Bros. Advisors
New York
$4.8M +$5.78M +201,888 New
JP Morgan Chase
12
JP Morgan Chase
New York
$4.25M -$1.08M -37,876 -18%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$4.08M +$2.12M +73,966 +76%
State Street
14
State Street
Massachusetts
$4.07M +$323K +11,280 +7%
Millennium Management
15
Millennium Management
New York
$3.72M -$1.55M -54,061 -26%
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$3.46M -$1.34M -46,663 -24%
RPAM
17
Rhenman & Partners Asset Management
Sweden
$3.05M -$338K -11,800 -8%
SCM
18
Sio Capital Management
New York
$3.01M +$695K +24,267 +24%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$2.83M -$699K -24,388 -17%
Northern Trust
20
Northern Trust
Illinois
$2.63M +$211K +7,359 +7%
RSCM
21
Rock Springs Capital Management
Maryland
$2.38M -$2.32M -81,000 -45%
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$2.1M – – –
State of New Jersey Common Pension Fund D
23
State of New Jersey Common Pension Fund D
New Jersey
$2.02M – – –
JGC
24
J. Goldman & Co
New York
$1.86M +$1.2M +41,997 +116%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$1.81M -$118K -4,119 -5%
1
2 3 4 5

RIGL Hedge Fund Activity: Q4 2016 in Review

107 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2016, worth a combined $210M — down 33% from $316M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RIGL and 14 opened new positions — a net loss of 13 holders — while 42 trimmed existing stakes and 31 added.

The largest buyer was Wellington Management Group, adding an estimated $16.5M. The largest seller was Boxer Capital, exiting entirely with an estimated $4.96M sold.

  • 107 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2016, down from 121 in Q3 2016.
  • Funds reported $210M of Rigel Pharmaceuticals stock for Q4 2016, down 33% quarter-over-quarter.
  • 14 funds opened new Rigel Pharmaceuticals positions in Q4 2016 and 27 closed out, a net change of -13 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2016 was Wellington Management Group, an estimated $16.5M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2016 was Boxer Capital, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2016.